Lymphocytes from 26 patients with primary gout were typed for eighteen antigens from A and B loci. An increased "relative risk" of the disease was established in patients carrying antigen HLA-B14, but the correlation is not sufficient for using HLA typing as a diagnostic tool in the gout. Nevertheless HLA-B14 seems to be one of the genetic factors which predispose to the appearance of the articular lesions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Discovery of the Novel HLA-C*01:282 Allele by Next-Generation Sequencing.
HLA
February 2025
Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital, Saskatoon, Saskatchewan, Canada.
The novel allele HLA-C*01:282 has a single non-synonymous mutation compared to HLA- C*01:02:01:01 in codon 100 in Exon 3.
View Article and Find Full Text PDFIdentification of the Novel HLA-DPB1*1483:01 Allele in a Deceased Hispanic/Latino Donor.
HLA
February 2025
HLA Laboratory, Westchester Medical Center, Valhalla, New York, USA.
We describe the novel HLA-DPB1*1483:01 allele found in a deceased Hispanic/Latino male.
View Article and Find Full Text PDFIdentification of the Novel HLA-A*01:478 Allele by Next-Generation Sequencing.
HLA
February 2025
Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA)-biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
HLA-A*01:478, a novel HLA class I allele detected by next-generation sequencing.
View Article and Find Full Text PDFCharacterisation of the Novel HLA-DQB1*03:571 Allele by Next-Generation Sequencing.
HLA
February 2025
Immunology Service, Clinical University Hospital Virgen de la Arrixaca (HCUVA)-Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
HLA-DQB1*03:571 differs from HLA-DQB1*03:09 by one nucleotide substitution in codon 170 in exon 3.
View Article and Find Full Text PDFEvaluation of donor specific antibodies after kidney transplantation in the era of donor-derived cell-free DNA.
Front Immunol
January 2025
Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Background: Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker for detecting graft injury in solid organ transplant recipients. Elevated dd-cfDNA levels are strongly associated with rejection and graft injury, especially antibody-mediated rejection (ABMR). While donor-specific antibodies (dnDSA) are crucial in ABMR, the relationship between dd-cfDNA levels and dnDSA features, such as DSA category, MFI and HLA target loci, remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!